Specifications
- Purity
- ≥98% (HPLC)
- Appearance
- White to off-white powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (20 mg/ml), ethanol (10 mg/ml)
Sertraline is a tetraline that inhibits monoamine transporters and acts as a potent highly selective serotonin reuptake inhibitor (SSRI), with affinity for the serotonin transporter (SERT), increasing availability of serotonin (5-hydroxytryptamine, 5-HT) in the brain and leading to antidepressant, anxiolytic and antiobsessional effects. Sertraline binds also to the dopamine transporter (DAT) and the sigma ?1 receptor (but not the ?2 receptor) with 100-fold lower affinity. It acts as an antagonist of the ?1 receptor, and is able to reverse ?1 receptor-dependent actions of fluvoxamine, a potent agonist of the receptor, in vitro. Sertraline displays antiproliferative activity on human colorectal carcinoma cells.
Synonyms | (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride, CP 51,974-1, Lustral, Seserine, Zoloft |
---|---|
Purity | ≥98% (HPLC) |
Appearance | White to off-white powder |
CAS-Number | 79559-97-0 |
Molecular Formula | C17H17NCl2 · HCl |
Molecular Weight | 342.69 |
Identity | 1H-NMR |
Solvents | DMSO (20 mg/ml), ethanol (10 mg/ml) |
Smiles | CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.Cl |
InChi Key | BLFQGGGGFNSJKA-XHXSRVRCSA-N |
Shipping | AMBIENT |
Short Term Storage | -20°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Hazard statements | H302-H400 |
Precautionary statements | P301 + P312 + P330 |
GHS Symbol | GHS07+GHS09 |
Signal word | Warning |
RIDADR | 3077 9 |
Transportation | Packing Group III |
References | (1) B.K. Koe, et al., J. Pharmacol. Exp. Ther. 226, 686 (1983), (2) W.M. Welch, et al., J. Med. Chem. 27, 1508 (1984), (3) J. Heym & B.K. Koe, J. Clin. Psychiatry 49, 40 (1988), (4) M. Tatsumi, et al., Eur. J. Pharmacol. 340, 249 (1997), (5) G. MacQueen, et al., CNS Drug Reviews 7, 1 (2001), (6) H.R. Khouzam, et al., Compr. Ther. 29, 47 (2003), (7) J.H. Meyer, et al., Am. J. Psych. 161, 826 (2004), (8) B. Lowe, et al., J. Affect. Disord. 87, 271 (2005), (9) Y. Albayrak & K. Hashimoto, Adv. Exp. Med. Biol. 964, 153 (2017) |
Quantity | 10 mg, 50 mg, Bulk |